Weill Cornell Lymphoma Program

05/05/2026

WATCH: Dr. Erin Mulvey discusses the changing treatment landscape for Richter Transformation, a rare condition where chronic lymphocytic leukemia ( ) or small lymphocytic (SLL) turns into a more aggressive form of lymphoma

At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.

05/01/2026

led by Dr. Jia Ruan and her collaborators aims to improve therapy options and survival rates for peripheral T-cell . Hear more from Dr. Ruan about this important work:

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

04/03/2026

Dr. Erin Mulvey spoke with Blood Cancers Today about how the phase 3 MURANO continues to inform targeted treatment approaches and management for chronic lymphocytic leukemia ( ):

The MURANO trial transformed CLL care. Explore 5 ways it drives venetoclax use, fixed-duration therapy, and personalized treatment today

03/31/2026

Watch Dr. Richard Furman discuss early findings from the CLL-17 looking at different treatment regimens for untreated chronic lymphocytic leukemia ( ): https://bit.ly/4v4CDs3 (cc: Oncology Learning Network)

Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.

03/26/2026

Dr. Jia Ruan led research evaluating triplet combination therapy for previously untreated mantle cell (MCL). She spoke with OncLive about the key takeaways:

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

03/12/2026

Watch Dr. John Allan discuss strategies for treating relapsed or refractory chronic lymphocytic leukemia (CLL), including sequencing considerations: https://bit.ly/46Ra1If (cc: Medscape)

Expert guidance is offered on treatment sequencing in relapsed or refractory CLL, including noncovalent BTKi, treatment resistance, and ongoing monitoring of patients to inform treatment selection.

02/17/2026

Dr. John Allan is speaking at Lymphoma Talk: New York, an in-person program on 3/5 hosted by Lymphoma Research Foundation where experts share information with patients about all forms of the disease. Register here:

Lymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides information about lymphoma in three breakout sessions.

02/12/2026

Join Dr. Erin Mulvey this afternoon for the Ask the Doctor About series hosted by the Lymphoma Research Foundation where she’ll be discussing how to navigate relapsed/refractory disease and answering live questions. Learn more and register:

Ask the Doctor is a national series of two-hour, topic-specific, community-based programs that combine a presentation by a medical doctor.

01/28/2026

Part 3 of the roundtable featured continued discussion on targeted approaches to CLL treatment. Hear more from our own Dr. Erin Mulvey: https://bit.ly/3YGTkuw

01/26/2026

In part 2 of the roundtable discussion, Dr. Erin Mulvey spoke alongside other experts about targeted treatment strategies for CLL:

This panel explores BTK and BCL-2 inhibitor combinations in CLL, focusing on fixed-duration therapy, MRD, PFS, and sequencing decisions.